Geneva, Oct. 9 -- International Clinical Trials Registry received information related to the study (NCT07850310) titled 'A Clinical Trial of MK-8644 in Healthy Participants and Participants With Psoriasis (MK-8644-001)' on Sept. 24.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).
Primary Sponsor: Merck Sharp & Dohme LLC
Condition:
Psoriasis
Healthy
Intervention:
Drug: MK-8644
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: October 6, 2026
Target Sample Size: 132
To know more, visit https://clinicaltrials.gov/study/NCT07850310
Published by HT Digital Content Service...